Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30468091 | 1.00 | MEN1 (0.48) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL17145147 | 0.89 | MEN1 (0.48) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL5718132 | 0.88 | MEN1 (0.52) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL11897994 | 0.88 | MEN1 (0.52) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL3654779 | 0.88 | MEN1 (0.52) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL11897993 | 0.88 | MEN1 (0.52) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Hydrochloric Acid SCHEMBL5718127 | 0.87 | MEN1 (0.51) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL15481367 | 0.84 | MEN1 (0.41) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL3652752 | 0.84 | MEN1 (0.63) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL2829344 | 0.82 | MEN1 (0.55) | MEN1LMNACYP3A4KMT2ANEU1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011021223-A2 | NOVEL SALTS OF ETHYL (3R, 4S, 5R)-4,5-IMINO-3-(L-ETHYLPROPOXY)-1- CVCLOHEXENE-1-CARBOXYLATE AND ITS USE | MSN LABORATORIES LIMITED (IN) | 2011-02-24 | — | — | WO | claimed |
| US-9150498-B2 | Process for the preparation of oseltamivir and methyl 3-epi-shikimate | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-10-06 | — | — | US | disclosed |
| US-9150498-B2 | Process for the preparation of oseltamivir and methyl 3-epi-shikimate | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-10-06 | — | — | US | disclosed |
| US-20140243537-A1 | PROCESS FOR THE PREPARATION OF OSELTAMIVIR AND METHYL 3-EPI-SHIKIMATE | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-08-28 | — | — | US | disclosed |
| US-20140243537-A1 | PROCESS FOR THE PREPARATION OF OSELTAMIVIR AND METHYL 3-EPI-SHIKIMATE | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-08-28 | — | — | US | disclosed |
| US-20140051756-A1 | METHOD FOR PREVENTING OR TREATING ARRHYTHMIA, METHOD FOR PREVENTING OR TREATING ATRIAL FIBRILLATION, MODEL OF SUSTAINED ATRIAL FIBRILLATION, METHOD FOR PRODUCING THE MODEL, AND METHOD FOR SCREENING FOR ATRIAL FIBRILLATION INHIBITOR | TOHO UNIVERSITY (JP) | 2014-02-20 | — | — | US | disclosed |
| US-20140051756-A1 | METHOD FOR PREVENTING OR TREATING ARRHYTHMIA, METHOD FOR PREVENTING OR TREATING ATRIAL FIBRILLATION, MODEL OF SUSTAINED ATRIAL FIBRILLATION, METHOD FOR PRODUCING THE MODEL, AND METHOD FOR SCREENING FOR ATRIAL FIBRILLATION INHIBITOR | TOHO UNIVERSITY (JP) | 2014-02-20 | — | — | US | disclosed |
| US-7915309-B2 | Deuterium-enriched oseltamivir | PROTIA, LLC (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915309-B2 | Deuterium-enriched oseltamivir | PROTIA, LLC (US) | 2011-03-29 | — | — | US | disclosed |
| WO-2011021223-A2 | NOVEL SALTS OF ETHYL (3R, 4S, 5R)-4,5-IMINO-3-(L-ETHYLPROPOXY)-1- CVCLOHEXENE-1-CARBOXYLATE AND ITS USE | MSN LABORATORIES LIMITED (IN) | 2011-02-24 | — | — | WO | disclosed |
| US-7473798-B2 | Derivatives of unsaturated, cyclic organic acids | ROCHE PALO ALTO LLC (US) | 2009-01-06 | — | — | US | disclosed |
| US-20080319064-A1 | DEUTERIUM-ENRICHED OSELTAMIVIR | PROTIA, LLC (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080319064-A1 | DEUTERIUM-ENRICHED OSELTAMIVIR | PROTIA, LLC (US) | 2008-12-25 | — | — | US | disclosed |
| US-20070197807-A1 | Derivatives of unsaturated, cyclic organic acids | GABEL RICHARD A | 2007-08-23 | — | — | US | disclosed |
| US-20070197807-A1 | Derivatives of unsaturated, cyclic organic acids | GABEL RICHARD A | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243537-A1 | PROCESS FOR THE PREPARATION OF OSELTAMIVIR AND METHYL 3-EPI-SHIKIMATE | CYP51A1, CYP2B6, CYP2C8 | MEN1 4095/4885LMNA 4533/4885CYP3A4 14/4885 |
| US-20140051756-A1 | METHOD FOR PREVENTING OR TREATING ARRHYTHMIA, METHOD FOR PREVENTING OR TREATING ATRIAL FIBRILLATION, MODEL OF SUSTAINED ATRIAL FIBRILLATION, METHOD FOR PRODUCING THE MODEL, AND METHOD FOR SCREENING FOR ATRIAL FIBRILLATION INHIBITOR | UGGT1, GUSB, KCNH1 | MEN1 3864/4885LMNA 1043/4885CYP3A4 192/4885 |
| US-20070197807-A1 | Derivatives of unsaturated, cyclic organic acids | ALOX5, VKORC1, ELOVL5 | MEN1 4812/4885LMNA 3327/4885CYP3A4 120/4885 |
| US-20080319064-A1 | DEUTERIUM-ENRICHED OSELTAMIVIR | HDHD5, SLC28A1, SAMHD1 | MEN1 4564/4885LMNA 4172/4885CYP3A4 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.